---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-057490"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:18:51.978077+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q1 DEXTENZA revenue $12.5M (+87% YoY); net loss $12.5M; guides FY22 product rev $55-60M

## Summary
- DEXTENZA net product revenue $12.5M in Q1 2022, up 87% from $6.7M in Q1 2021.
- Net loss $12.5M ($0.16 basic loss per share) vs. net income $3.1M in Q1 2021; includes $7M non-cash derivative liability adjustment.
- Cash and equivalents $145.4M as of March 31, 2022; company believes sufficient through 2023.
- Guides FY2022 DEXTENZA revenue $55-60M (26-38% growth); expands commercial team with VP Steve Meyers for office setting.
- OTX-TKI Phase 1 fully enrolled, six-month data expected Q3 2022; OTX-TIC Phase 2 dosing began, triggering $2M milestone from AffaMed.

## SEC filing metadata
- accession: 0001104659-22-057490
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465922057490/0001104659-22-057490-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465922057490/tm2214885d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-057490
- JSON: https://secwatch.observer/filing/0001104659-22-057490.json
- Plain text: https://secwatch.observer/filing/0001104659-22-057490.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.